Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
Fatigue, depression and sleep disturbances in Iranian patients with multiple sclerosis.
Positive year one results from Biogen Idec's Phase 3 advance trial of PLEGRIDY™ (peginterferon beta-1a) presented at AAN meeting
Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment.
Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.
Laquinimod Phase IIa Study in Active Crohn's Disease
Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1.
Multigate Quality Doppler Profiles and Morphological/Hemodynamic Alterations in Multiple Sclerosis Patients.
Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results.
Genetics of multiple sclerosis: swimming in an ocean of data.
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
Substance Name: Amiloride
Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration.
Daclizumab (anti-CD25) in multiple sclerosis.
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Food and Drug Administration Approval Letter for Alemtuzumab
Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2.
Guillain-Barré syndrome: clinical profile and management.
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
English Court of Appeal finds in favor of Teva on Copaxone(R) patent litigation and upholds validity of Copaxone patent until May 2015
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation.
Clinical and MRI characterization of MS patients with a pure and severe cognitive onset.
Cross-cultural Adaptation, Reliability, and Validity of the BICAMS in Brazil.

Pages